

Recommendations of an expert group for cardiac assessment of non-dystrophic myotonic adult patients treated with mexiletine

Vicart S¹, **Wahbi K**², Duchateau J³, Sellal JM⁴, Deharo JC⁵, Bassez G⁶, Salort-Campana E⁷, Labombarda F⁸.

1. Muscle Channelopathies Reference Center, Service of Neuro-Myology, Assistance Publique-Hôpitaux de Paris, University Hospital Pitié-Salpêtrière, Sorbonne Université, INSERM UMR 974, Institute of Myology, Paris, France
2. Centre de référence constitutif des maladies neuromusculaires, département de cardiologie, Ap-Hp Cochin, Paris, France
3. Service de cardiologie, électrophysiologie et stimulation cardiaque, Hôpital Haut Lévêque, CHU de Bordeaux, France
4. Département de cardiologie, CHU de Nancy, France
5. Département de cardiologie, Hôpital de la Timone, CHU de Marseille, France
6. Centre de référence constitutif des maladies neuromusculaires, service de neuro-myologie, Ap-Hp Pitié-Salpêtrière – Paris, France
7. Centre de référence neuromusculaire coordonnateur PACA Réunion Rhône alpes, service du Pr Attarian, Hôpital de la Timone, CHU de Marseille, France
8. Département de cardiologie, CHU de Caen, France

Abstract topic: Topic 1 - Understanding phenotypic and genetic diversity in neuromuscular disorders

Mexiletine (NaMuscla™) is indicated for the symptomatic treatment of myotonia in adults with non-dystrophic myotonia (NDM). A cardiac assessment is required as mexiletine may have a pro-arrhythmic effect. Long-term safety data supporting use of mexiletine in patients with NDM combined with the extensive clinical experience of an expert group resulted in creation of an algorithm for cardiac monitoring of NDM patients treated with Mexiletine.

To define the treatment algorithm, several workshops with experts including 3 neurologists and 5 cardiologists from different French neuromuscular reference centres were set up. These workshops aimed to define the screening and surveillance tools required to avoid cardiac events in mexiletine-treated patients.

The recommendations are based on the summary of product characteristics (SmPC), a review of the literature on the safety of mexiletine-treated NDM patients and on the expertise of the authors.

The expert group concluded that the cardiac safety profile of mexiletine in NDM patients appears similar to that of the general population. Therefore, NDM patients treated with Mexiletine should be monitored as any patient treated with a class 1b anti-arrhythmic. Cardiac assessment should be performed before initiation of mexiletine and at least every 2 years under treatment.

In summary, an algorithm for cardiac safety monitoring in patients with NDM treated with mexiletine has been developed to assist the neurologists and cardiologists managing these patients.

Data were first presented at the 9th Congress of the European Academy of Neurology, Budapest, July 1–4, 2023. Abstract # A-23-06846.

Disclosures:

All authors declare consulting fees from Lupin.